Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on July 14, 2026, with the earliest event reported on that date. The filing details the entry into a Material Definitive Agreement for a public equity offering that closed on July 16, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10.05 million.
- Securities Issued to Institutional Investors: 8,571,429 shares of Common Stock and accompanying warrants to purchase up to 8,571,429 shares.
- Offering Price (Institutional): $1.05 per share of Common Stock and accompanying warrant.
- Securities Issued to Insiders: 721,649 shares of Common Stock and accompanying warrants to purchase up to 721,649 shares.
- Offering Price (Insiders): $1.455 per share of Common Stock and accompanying warrant.
- Placement Agent Fees: 7.0% of gross proceeds in cash, plus a warrant to purchase up to 465,157 shares (5.0% of aggregate shares sold) at an exercise price of $1.3125.
- Other Expenses: $35,000 for non-accountable expenses, $50,000 for legal fees, and $15,950 for clearing fees.
- Warrant Terms: Exercise price of $1.31 per share ($1.33 for Insiders); exercisable beginning six months after issuance or upon authorized share increase; five-and-a-half-year term.
Material Changes and Use of Proceeds
The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The filing does not provide comparative financial metrics (revenue, profit, cash flow, or margins) as this is a transactional report rather than a periodic financial statement. The transaction results in significant dilution to existing shareholders due to the issuance of new shares and warrants.
Outlook, Risks, and Contingencies
- Shareholder Approval Requirement: The Company must obtain stockholder approval to amend its certificate of incorporation to increase authorized shares sufficient for the full exercise of the Common Warrants.
- Timeline for Approval: A proxy statement will be filed within 45 days of closing. If approval is not obtained at the first meeting, the Company must call a meeting every 60 days thereafter until approval is obtained or warrants are no longer outstanding.
- Warrant Exercisability: Warrants cannot be exercised until the later of six months post-issuance or the "Authorized Share Increase Date."
- Legal Disclaimer: Representations and warranties in the Purchase Agreement are for the benefit of the parties and do not constitute statements of fact for investors.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7.0% placement fee and other expenses.
- Confirm the timeline for the shareholder vote on the authorized share increase amendment.
- Assess the dilution impact of the 8,571,429 new shares, 721,649 insider shares, and the aggregate warrants issued (including the placement agent warrant).
- Review the Company's current cash position to determine the runway provided by the $10.05 million gross proceeds.